Hemophilia, reimbursability of emicizumab approved at NHS charge
MONZA (ITALPRESS) – The Italian Medicines Agency (AIFA), on Aug. 21, 2024, approved the reimbursability of emicizumab under the SSN for routine prophylaxis of bleeding episodes in patients with hemophilia A, without factor VIII inhibitors, who have moderate disease with […]
Hemophilia, reimbursability of emicizumab approved at NHS charge Read More »